214 related articles for article (PubMed ID: 32862848)
41. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
42. Chronic myeloproliferative disorders: a tyrosine kinase tale.
De Keersmaecker K; Cools J
Leukemia; 2006 Feb; 20(2):200-5. PubMed ID: 16341034
[TBL] [Abstract][Full Text] [Related]
43. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
44. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
Cortes JE; Talpaz M; Beran M; O'Brien SM; Rios MB; Stass S; Kantarjian HM
Cancer; 1995 Jan; 75(2):464-70. PubMed ID: 7812917
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Beran M; Shen Y; Onida F; Wen S; Kantarjian H; Estey E
Leuk Lymphoma; 2006 Mar; 47(3):417-23. PubMed ID: 16396764
[TBL] [Abstract][Full Text] [Related]
46. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
47. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
Kantarjian HM; Shtalrid M; Kurzrock R; Blick M; Dalton WT; LeMaistre A; Stass SA; McCredie KB; Gutterman J; Freireich EJ
Am J Med; 1988 Nov; 85(5):639-44. PubMed ID: 3189367
[TBL] [Abstract][Full Text] [Related]
48. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
49. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia.
Costello R; Sainty D; Lafage-Pochitaloff M; Gabert J
Leuk Lymphoma; 1997 Apr; 25(3-4):225-32. PubMed ID: 9168433
[TBL] [Abstract][Full Text] [Related]
50. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.
Hirsch-Ginsberg C; LeMaistre AC; Kantarjian H; Talpaz M; Cork A; Freireich EJ; Trujillo JM; Lee MS; Stass SA
Blood; 1990 Sep; 76(6):1214-9. PubMed ID: 2205309
[TBL] [Abstract][Full Text] [Related]
51. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
[TBL] [Abstract][Full Text] [Related]
52. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
53. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
54. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.
Morris CM
Methods Mol Biol; 2011; 730():33-61. PubMed ID: 21431633
[TBL] [Abstract][Full Text] [Related]
55. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
56. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Tyner JW; Gotlib J
Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
[TBL] [Abstract][Full Text] [Related]
57. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
58. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
59. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
[TBL] [Abstract][Full Text] [Related]
60. Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children.
Berking AC; Flaadt T; Behrens YL; Yoshimi A; Leipold A; Holzer U; Lang P; Quintanilla-Martinez L; Schlegelberger B; Reiter A; Niemeyer C; Strahm B; Göhring G
Cancer Genet; 2023 Apr; 272-273():29-34. PubMed ID: 36657267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]